SI2656070T1 - Ugotavljanje učinkovitosti živega rekombinantnega antimikobakterijskega cepljenja - Google Patents

Ugotavljanje učinkovitosti živega rekombinantnega antimikobakterijskega cepljenja

Info

Publication number
SI2656070T1
SI2656070T1 SI201130785A SI201130785A SI2656070T1 SI 2656070 T1 SI2656070 T1 SI 2656070T1 SI 201130785 A SI201130785 A SI 201130785A SI 201130785 A SI201130785 A SI 201130785A SI 2656070 T1 SI2656070 T1 SI 2656070T1
Authority
SI
Slovenia
Prior art keywords
efficacy
determination
recombinant anti
live recombinant
mycobacterial
Prior art date
Application number
SI201130785A
Other languages
English (en)
Inventor
Christiane Desel
Stefan H.E. Kaufmann
Silke Bandermann
Leander Grode
Original Assignee
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V.
Vakzine Projekt Management Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., Vakzine Projekt Management Gmbh filed Critical Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V.
Publication of SI2656070T1 publication Critical patent/SI2656070T1/sl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI201130785A 2010-12-21 2011-12-21 Ugotavljanje učinkovitosti živega rekombinantnega antimikobakterijskega cepljenja SI2656070T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061425442P 2010-12-21 2010-12-21
PCT/EP2011/073609 WO2012085099A1 (en) 2010-12-21 2011-12-21 Determination of the efficacy of an anti-mycobacterial vaccination
EP11805020.2A EP2656070B9 (en) 2010-12-21 2011-12-21 Determination of the efficacy of a live recombinant anti-mycobacterial vaccination

Publications (1)

Publication Number Publication Date
SI2656070T1 true SI2656070T1 (sl) 2016-05-31

Family

ID=45446021

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130785A SI2656070T1 (sl) 2010-12-21 2011-12-21 Ugotavljanje učinkovitosti živega rekombinantnega antimikobakterijskega cepljenja

Country Status (25)

Country Link
US (1) US8906389B2 (sl)
EP (1) EP2656070B9 (sl)
JP (1) JP6055780B2 (sl)
KR (1) KR101882040B1 (sl)
CN (1) CN103492877B (sl)
AU (1) AU2011347266B2 (sl)
BR (1) BR112013015878B1 (sl)
CA (1) CA2822715C (sl)
CU (1) CU20130084A7 (sl)
CY (1) CY1117412T1 (sl)
DK (1) DK2656070T3 (sl)
EA (1) EA029833B9 (sl)
ES (1) ES2569035T3 (sl)
HK (1) HK1192322A1 (sl)
HR (1) HRP20160558T1 (sl)
HU (1) HUE027781T2 (sl)
MX (1) MX345961B (sl)
PL (1) PL2656070T3 (sl)
PT (1) PT2656070E (sl)
RS (1) RS54770B1 (sl)
SG (1) SG191331A1 (sl)
SI (1) SI2656070T1 (sl)
SM (1) SMT201600149B (sl)
UA (2) UA113282C2 (sl)
WO (1) WO2012085099A1 (sl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543698A1 (en) * 2018-03-20 2019-09-25 Helmholtz-Zentrum für Infektionsforschung GmbH Method for determining vaccine efficacy in an individual and means therefore

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
EP1137769B1 (en) * 1998-11-10 2008-09-03 University Of Rochester Methods for the generation of dna libraries
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
JP2001215224A (ja) * 1999-11-25 2001-08-10 Hitachi Chem Co Ltd 免疫反応のアッセイ法、免疫学的判定法及びアッセイキット
CA2523084C (en) 2003-04-23 2012-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Tuberculosis vaccine with improved efficacy
AU2006214473A1 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
US20080031882A1 (en) * 2006-06-19 2008-02-07 Liang Spencer C Methods of modulating IL-22 and IL-17
CN101329230B (zh) * 2008-07-14 2010-10-20 中国人民解放军第三军医大学 改进的免疫荧光细胞染色方法
JP2010051307A (ja) * 2008-07-28 2010-03-11 Eisai R & D Management Co Ltd Th17細胞およびTreg細胞の分化誘導を調節する物質のスクリーニング方法
DK2341928T3 (en) * 2008-10-20 2015-09-28 Univ Zürich MYCOBACTERIUM TUBERCULOSIS VACCINE
BRPI1011919A2 (pt) * 2009-06-29 2017-09-26 Childrens Medical Center vacinas e composições contra streptococcus pneumoniae

Also Published As

Publication number Publication date
CU20130084A7 (es) 2013-12-27
KR20140020243A (ko) 2014-02-18
SG191331A1 (en) 2013-07-31
US8906389B2 (en) 2014-12-09
PT2656070E (pt) 2016-06-17
WO2012085099A1 (en) 2012-06-28
BR112013015878B1 (pt) 2020-10-27
US20130280739A1 (en) 2013-10-24
AU2011347266A1 (en) 2013-07-25
SMT201600149B (it) 2016-07-01
UA112067C2 (uk) 2016-07-25
EP2656070B9 (en) 2017-01-04
ES2569035T3 (es) 2016-05-06
CN103492877B (zh) 2015-04-01
HRP20160558T1 (hr) 2016-06-17
EA029833B1 (ru) 2018-05-31
JP2014502841A (ja) 2014-02-06
DK2656070T3 (en) 2016-06-13
CA2822715A1 (en) 2012-06-28
KR101882040B1 (ko) 2018-07-25
UA113282C2 (xx) 2017-01-10
JP6055780B2 (ja) 2016-12-27
CA2822715C (en) 2019-04-30
BR112013015878A2 (pt) 2016-10-04
EP2656070B1 (en) 2016-03-09
EA201300738A1 (ru) 2013-12-30
HUE027781T2 (en) 2016-11-28
HK1192322A1 (en) 2014-08-15
MX345961B (es) 2017-02-28
MX2013007244A (es) 2014-01-17
EA029833B9 (ru) 2018-06-29
RS54770B1 (sr) 2016-10-31
CY1117412T1 (el) 2017-04-26
AU2011347266B2 (en) 2016-07-21
EP2656070A1 (en) 2013-10-30
PL2656070T3 (pl) 2017-01-31
CN103492877A (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
IL223206A0 (en) Vaccine formulations
GB201005005D0 (en) New vaccine
GB201015132D0 (en) Vaccine composition
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
HK1249859A1 (zh) Pcsk9肽疫苗
ZA201301950B (en) Bvdv vaccine
GB201014965D0 (en) Vaccine
PL2359816T3 (pl) Formulacje aripiprazolu
AP2013006687A0 (en) Formulations
PT2536400E (pt) Medicamento contendo myramistin
GB201007255D0 (en) Self-retracting actuator
ZA201303842B (en) Adjuvants for insecticides
SI2656070T1 (sl) Ugotavljanje učinkovitosti živega rekombinantnega antimikobakterijskega cepljenja
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
ZA201302154B (en) Vaccine
AP2013006689A0 (en) Formulations
GB201010056D0 (en) Polypeptide vaccine
GB201010058D0 (en) Peptide vaccine
GB201012283D0 (en) Vaccine
GB201007588D0 (en) Vaccine
GB201007589D0 (en) Vaccine
GB201008795D0 (en) Vaccines
GB201008793D0 (en) vaccines
GB201008788D0 (en) Vaccines